SCHEMBL1138693

SCHEMBL1138693

Cc1ccc(B(Oc2cccnc2C(=O)O)c2ccc(O)cc2)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 4/20 0.37
RAB9A P51151 3/20 0.37
KMO O15229 2/20 0.36
MAPT P10636 4/20 0.36
TP53 P04637 2/20 0.36
STAT1 P42224 1/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
RECQL P46063 1/20 0.35
MYC P01106 1/20 0.34
NPSR1 Q6W5P4 2/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
BLM P54132 1/20 0.34
AGER Q15109 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL447506 0.94 KDM4E (0.42) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL1138576 0.79 MEN1 (0.39) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL4453565 0.79 KDM4E (0.35) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL1138695 0.78 NPC1 (0.37) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL1138595 0.77 MRGPRX4 (0.40) KDM4ENPC1RAB9AMAPTALDH1A1
SCHEMBL16152204 0.75 MEN1 (0.40) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL5166277 0.75 NPSR1 (0.52) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL442638 0.74 NPC1 (0.39) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL29696120 0.74 NPC1 (0.39) MEN1KMT2AKDM4EMAPK1NPC1
SCHEMBL447507 0.73 NPC1 (0.38) MEN1KMT2AKDM4EMAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765358-B1 TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES ANACOR PHARMACEUTICALS INC (US) 2011-02-23 EP disclosed
US-7652000-B2 Boron-containing compounds and methods of use ANACOR PHARMACEUTICALS, INC. (US) 2010-01-26 US disclosed
EP-1765358-A2 TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES Anacor Pharmaceuticals, Inc. (US) 2007-03-28 EP disclosed
US-20060009422-A1 Boron-containing compounds and methods of use ANACOR PHARMACEUTICALS, INC. 2006-01-12 US disclosed
WO-2005123094-A2 TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES ANACOR PHARMACEUTICALS, INC. (US) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009422-A1 Boron-containing compounds and methods of use BROX, BTD, PBDC1 MEN1 894/4885KMT2A 4784/4885KDM4E 4783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.